Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07448194) titled 'A Phase Ia Clinical Trial of HW241045' on Feb. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Condition:
Healthy Volunteers
IPF
Intervention:
Drug: HW241045
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: November 24, 2025
Target Sample Size: 56
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/stu...